ArticleEcho research and practice2026
The impact of right ventricular free wall strain on current international echocardiography guidelines for the assessment of pulmonary hypertension.
Article in Echo research and practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCurrent guidelines define pulmonary hypertension (PH) as a mean pulmonary artery pressure (mPAP) >20mmHg at right heart catheterisation (RHC). International transthoracic echocardiography (TTE) PH guidelines recommend a multi-parameter assessment to estimate PH probability. Effectiveness of the inclusion of right ventricular free wall strain (RVFWS) has not been established using real world data. STUDY
aimsTo determine the accuracy of current European and American TTE PH guidance in detecting PH in patients attending a UK PH centre. The impact of addition of RVFWS to the efficacy of the European and American guidance was also evaluated.
methodsTTE with subsequent RHC (within 1.4 months) were undertaken in patients with suspicion of PH, referred for first time investigations. Echocardiographic variables were assessed in accordance with current European and American TTE guidance.
resultsOf 549 patients assessed, 431 (79%) had RHC confirmed PH (average mPAP = 41mmHg). Sensitivity / specificity for detecting PH was calculated for the European Society of Cardiology (ESC) TTE PH recommendations (83% / 65% respectively); ESC + RVFWS (92% / 62% respectively); American Society of Echocardiography (ASE) TTE PH recommendations (89% / 49% respectively); ASE + RVFWS (96% / 36% respectively); TTE PASP > 35mmHg alone (75% / 73% respectively); TTE TRV > 2.8 m/s alone (77% / 78% respectively). Of those with RHC PH 3 (1%) subjects with a TRV > 2.8 m/s and 7 (3%) with a PASP > 35mmHg had no supporting signs of PH. Using TTE PASP > 35mmHg or TRV >2.8m/s with at least 2 abnormal TTE parameters (including RVFWS) gave similar sensitivity / specificity (74% / 79% vs 73% / 87% respectively). In those with RHC PH and TTE PASP >35mmHg or TRV >2.8m/s the significant majority had at least 2 TTE PH markers (99% & 97%). Whilst TTE PASP and RHC PASP correlation was good (r = 0.745), accuracy was poor with limits of agreements as high as 44mmHg (range = -29 to 44mmHg). In those with no measurable tricuspid regurgitation, 64% (n = 49) had RHC PH (11% of whole cohort); in those where TTE PASP <35mmHg 23% (n = 70) had RHC PH. In those felt to have an ESC PH low TTE probability 44% (n = 60) had RHC PH (14% of whole cohort). Incorporating RVFWS improved detection in those with a ESC low TTE PH probability, reducing false negatives by 43%.
conclusionCurrent TTE PH algorithms lack sensitivity to detect patients with milder haemodynamic forms of PH. This can be improved with the addition of RVFWS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.